Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00505219 · ClinicalTrials.gov registry record · Phase 3
Ixmyelocel-T Treatment of Patients With Osteonecrosis of the Femoral Head
A Phase 3 study, sponsored by Vericel Corporation.
- Completed
- Registry status
- Phase 3
- Development phase
- 11
- Enrollment target
NCT00505219: Completed Phase 3 study, sponsored by Vericel Corporation.
NCT00505219 is a Phase 3 study that has completed, run by Vericel Corporation. The registered enrollment target is 11 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00505219, a Phase 3 study, has completed, sponsored by Vericel Corporation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 11 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if Ixmyelocel-T grafting with demineralized bone matrix bound in autologous plasma after core decompression surgery is superior to core decompression with demineralized bone matrix bound in autologous plasma in preventing progression of osteonecrosis to a more severe disease stage (Stage II to III or higher) from the time of surgery until 24 months later, in patients with University of Pennsylvania (UPenn) Stage IIB or C disease at diagnosis.
Interventions
- BIOLOGICAL Ixmyelocel-T
- OTHER Standard of Care Only
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2007-09 |
| Est. Completion | 2010-12 |
| Phase | Phase 3 |
What the finished NCT00505219 record still lists
NCT00505219 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Ixmyelocel-T is the first listed.
NCT00505219 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00505219 about?
NCT00505219 is a clinical study titled "Ixmyelocel-T Treatment of Patients With Osteonecrosis of the Femoral Head". The purpose of this study is to determine if Ixmyelocel-T grafting with demineralized bone matrix bound in autologous plasma after core decompression surgery is superior to core decompression with demineralized bone matrix bound in autologous plasma in preventing progression of osteonecrosis to a mo...
What is the current status of trial NCT00505219?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 11 participants. The study started on 2007-09. Estimated completion is 2010-12.
What interventions are being tested in trial NCT00505219?
The interventions under investigation include: Ixmyelocel-T (BIOLOGICAL), Standard of Care Only (OTHER).
Who is sponsoring clinical trial NCT00505219?
This trial is sponsored by Vericel Corporation, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00505219's enrollment target sits among peer trials
11 1989th of 2000 higher than 12 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia